IVIEW-1502

IVIEW-1502 is an investigational in-situ gel-forming nasal formulation combining povidone-iodine (PVP-I) and budesonide for the treatment of chronic rhinosinusitis (CRS). Developed by IView Therapeutics in collaboration with Dr. Amin Javer, the formulation is designed as a long-acting nasal spray that utilizes a polysaccharide gel matrix to prolong drug retention in the nasal cavity. Upon contact with nasal mucus ions, the suspension undergoes a solution-to-gel phase transition, which increases residence time and reduces mucociliary clearance. Povidone-iodine acts as a broad-spectrum antiseptic with antibacterial and antifungal properties to address potential infectious components, while budesonide serves as a corticosteroid to reduce underlying inflammation. The drug is primarily intended for use following endoscopic sinus surgery (ESS) to improve postoperative healing and endoscopic outcomes in adult patients with CRS.

Other names

PVP-I/Budesonide GelPovidone-Iodine and Budesonide Gel-Forming SuspensionIntra-sinus Povidone-iodine/Budesonide Gel